Hisham Elhaddad
Co-Founder and Managing Partner @ HOF Capital
New York, United States
Hisham Elhaddad is a Series B investor at HOF Capital in New York focused on Biotechnology and SaaS. Hisham Elhaddad is based out of New York, New York and is the Co-Founder and Managing Partner of HOF Capital. Hisham previously worked at Entrepreneurs Roundtable Accelerator as a Investment Associate. Hisham Elhaddad attended the Boston University.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 22%
Last updated:
For AI agents: llms.txt
Industries Hisham Elhaddad invests in
Stages Hisham Elhaddad invests in
Countries Hisham Elhaddad invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 2 (22%)
- SaaS 1 (11%)
- Energy 1 (11%)
- Medical 1 (11%)
- Nuclear 1 (11%)
Stage
- Series B 3 (33%)
- Series A 2 (22%)
- Secondary Market 2 (22%)
- Series C 1 (11%)
Country
- United States 4 (44%)
- Croatia 2 (22%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Bugatti Rimac is a Motor Cycle Manufacturing Company. | Secondary Market / Apr 24, 2026 | ||
| Rimac is a technology powerhouse that manufactures electric hypercars and provides full technology solutions to global automotive manufacturers. Founded in 2009 with headquarters in Croatia, Rimac started as a garage project and grew into a globally recognized technology leader, built upon the passion and vision of the company's Founder andCEO Mate Rimac. It has challenged the status-quo with the vision to revolutionize and reinvent the sports car with its unique technology thus successfully tackling the electrification challenge set upon the automotive industry. | Secondary Market / Apr 24, 2026 | ||
| Commonwealth Fusion Systems develops fusion energy systems using high-temperature superconducting (HTS) magnets to create compact tokamak reactors. It is building SPARC, a demonstration device designed to achieve net energy gain from fusion and laying the groundwork for ARC, a grid-connected fusion power plant targeting early 2030s operation. Thecompany partners with MIT and manufactures its HTS magnets and related components, applying peer-reviewed science in its firewalling of plasma and reactor engineering. It has introduced innovations like the PIT VIPER superconducting cable to support pulsed-power magnet systems and accelerate readiness for commercial fusion. | $863M / Series B / Aug 27, 2025 | ||
| Codesphere is your Zeroconfig Cloud. No config - just code and run web apps from your browser. Team work on distributed full stack Typescript, and benefit from our automatic deployments, scaling, tests, and security / privacy audits. We optimize each and every detail to keep things simple for you. Codesphere is next level programming. | $30.9M / Series A / May 17, 2024 | ||
| BillionToOne is a precision diagnostics company that quantifies biology to create molecular diagnostics accurate, efficient, and accessible for all. The company's patent-pending molecular counter platform is a technology platform that can accurately count the DNA molecules to the single-count level. BillionToOne's mission is to makepre-natal testing safe and affordable for every expecting mother. Its novel technology can detect even single-gene disorders such as thalassemia through a simple blood test. They are replacing amniocentesis, an invasive and risky procedure that has a high miscarriage risk, with a safe and affordable blood test, starting in developing countries.BillionToOne was founded in 2016 and is headquartered in Menlo Park, California. | $125M / Series C / Mar 30, 2022 | ||
| BillionToOne is a precision diagnostics company that quantifies biology to create molecular diagnostics accurate, efficient, and accessible for all. The company's patent-pending molecular counter platform is a technology platform that can accurately count the DNA molecules to the single-count level. BillionToOne's mission is to makepre-natal testing safe and affordable for every expecting mother. Its novel technology can detect even single-gene disorders such as thalassemia through a simple blood test. They are replacing amniocentesis, an invasive and risky procedure that has a high miscarriage risk, with a safe and affordable blood test, starting in developing countries.BillionToOne was founded in 2016 and is headquartered in Menlo Park, California. | $55M / Series B / Jun 15, 2021 | ||
| Insitro is an operator of a data-driven drug discovery and development company that utilizes machine learning and high-throughput biology to transform the way that drugs are discovered and delivered to patients.The company uses state-of-the-art technologies from bioengineering enabling it to generate high-throughput, functional genomic data setsand aligning them with patient data via novel machine learning methods, thereby building predictive models that can accelerate target selection and the design and development of effective therapeutics.In 2018, Daphne Koller established Insitro in South San Francisco, California.. | $143M / Series B / May 26, 2020 | ||
| BillionToOne is a precision diagnostics company that quantifies biology to create molecular diagnostics accurate, efficient, and accessible for all. The company's patent-pending molecular counter platform is a technology platform that can accurately count the DNA molecules to the single-count level. BillionToOne's mission is to makepre-natal testing safe and affordable for every expecting mother. Its novel technology can detect even single-gene disorders such as thalassemia through a simple blood test. They are replacing amniocentesis, an invasive and risky procedure that has a high miscarriage risk, with a safe and affordable blood test, starting in developing countries.BillionToOne was founded in 2016 and is headquartered in Menlo Park, California. | $15M / Series A / Mar 10, 2020 | ||
| BillionToOne is a precision diagnostics company that quantifies biology to create molecular diagnostics accurate, efficient, and accessible for all. The company's patent-pending molecular counter platform is a technology platform that can accurately count the DNA molecules to the single-count level. BillionToOne's mission is to makepre-natal testing safe and affordable for every expecting mother. Its novel technology can detect even single-gene disorders such as thalassemia through a simple blood test. They are replacing amniocentesis, an invasive and risky procedure that has a high miscarriage risk, with a safe and affordable blood test, starting in developing countries.BillionToOne was founded in 2016 and is headquartered in Menlo Park, California. | $15M / Series A / Mar 13, 2019 |
Co-Investors
About HOF Capital
HOF Capital is a global multistage VC firm with $1 billion in AUM that partners with ambitious entrepreneurs from idea to IPO.
HOF Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Fady Yacoub
Co-Founder and Partner
|
|||
|
Hisham Elhaddad
Co-Founder and Managing Partner
|
|||
Onsi Sawiris
Co-Founder and Managing Partner
|
|||
Troy Shen
Senior Associate
|
|||
Victor Wang
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Hisham Elhaddad invest in?
Hisham Elhaddad invests primarily in Biotechnology, SaaS and Energy startups, most often at Series B and Series A stage. Most of the 9 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Hisham Elhaddad?
Public channels for Hisham Elhaddad include LinkedIn and X (Twitter). For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Hisham Elhaddad last invest?
The most recent investment recorded for Hisham Elhaddad closed in Apr 2026. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
